Author Interviews, Neurological Disorders, Parkinson's / 24.04.2023
Parkinson’s Disease: Extended Release Levodopa Tested to Reduce Motor Fluctuations
MedicalResearch.com Interview with:
[caption id="attachment_60323" align="alignleft" width="150"] Dr. Espay[/caption]
Alberto J. Espay, MD, MSc, FAAN
Professor of Neurology
Director and Endowed Chair
Gardner Family Center for Parkinson's disease and Movement Disorders
University of Cincinnati Academic Health Center
MedicalResearch.com: What is the background for this study?
Response: This study was meant to address the gap that current oral levodopa formulations do not suffice to lessen motor fluctuations in people with Parkinson’s disease. IPX203 is a unique extended-release formulation of levodopa.
Dr. Espay[/caption]
Alberto J. Espay, MD, MSc, FAAN
Professor of Neurology
Director and Endowed Chair
Gardner Family Center for Parkinson's disease and Movement Disorders
University of Cincinnati Academic Health Center
MedicalResearch.com: What is the background for this study?
Response: This study was meant to address the gap that current oral levodopa formulations do not suffice to lessen motor fluctuations in people with Parkinson’s disease. IPX203 is a unique extended-release formulation of levodopa.